Evolus, Inc. (EOLS) - Dilution Analysis

10-Q filing | 65.2M shares outstanding

10-Q filing | 64.5M shares outstanding

10-Q filing | 63.7M shares outstanding

10-K filing | 62.0M shares outstanding

10-Q filing | 63.1M shares outstanding

10-Q filing | 62.7M shares outstanding

10-Q filing | 58.8M shares outstanding

8-K filing: Evolus, Inc. completed a public offering of 3,554,000 shares of its common stock at a price of $14.07 per share, resulting in net proceeds of approximately $46.9 million. ($49.9M proceeds)

10-K filing | 56.9M shares outstanding

8-K filing: Evolus, Inc. issued 610,000 shares of its common stock to Symatese Aesthetics S.A.S. as consideration for a license agreement granting Evolus exclusive rights to commercialize and distribute dermal filler products in Europe.

10-Q filing | 57.0M shares outstanding

10-Q filing | 56.9M shares outstanding

S-3/A filing: Evolus, Inc. is offering common stock with an aggregate offering price of up to $50,000,000 through an at-the-market offering via SVB Securities, with the net proceeds planned for business development, working capital, and other general corporate purposes.

8-K filing: Evolus, Inc. entered into a License, Supply and Distribution Agreement with Symatese S.A.S for dermal filler product candidates, amended their Loan Agreement with BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, and granted David Moatazedi 560,000 performance restricted stock units.

10-Q filing | 56.5M shares outstanding

S-3/A filing: Evolus, Inc. is offering common stock with an aggregate offering price of up to $50,000,000 through an at-the-market offering via SVB Securities, with the net proceeds planned for business development, working capital and other general corporate purposes.

S-3 filing: This is an S-3 filing for an at-the-market offering of common stock with an aggregate offering price of up to $50,000,000. The company intends to use the net proceeds from this offering for business development, working capital and other general corporate purposes.

10-K filing | 56.1M shares outstanding

10-Q filing | 56.2M shares outstanding

10-Q filing | 56.1M shares outstanding

10-Q filing | 55.7M shares outstanding

10-K filing | 55.7M shares outstanding

10-Q filing | 55.0M shares outstanding

10-Q filing | 51.2M shares outstanding

10-Q filing | 54.1M shares outstanding

8-K filing: Evolus, Inc. completed a public offering of 9,000,000 firm shares and 1,350,000 option shares of common stock at a public offering price of $9.50 per share, resulting in net proceeds of $92.1 million. ($92.1M proceeds)

8-K filing: Evolus, Inc. completed a public offering of 9,000,000 shares of common stock at a price of $9.50 per share, resulting in net proceeds of approximately $80.1 million, with underwriters having an option to purchase up to 1,350,000 additional shares. ($85.5M proceeds)

10-K filing | 43.7M shares outstanding

8-K filing: Evolus, Inc. issued 3,136,869 shares of common stock to Daewoong Pharmaceuticals Co., Ltd. upon conversion of a convertible promissory note with an outstanding principal balance of $40,779,303 at a conversion price of $13.00 per share.

8-K filing: Evolus, Inc. issued 6,762,652 shares of its common stock to Medytox, Inc. pursuant to a Share Issuance Agreement in connection with a settlement agreement.

10-Q filing | 33.7M shares outstanding

10-Q filing | 33.7M shares outstanding

10-Q filing | 33.7M shares outstanding

10-K filing | 33.7M shares outstanding